Fierce Biotech August 28, 2024
Amid a yearslong clinical trial decline in the U.K., a new public-private partnership has emerged in efforts to reinvigorate the country’s pharmaceutical testing prowess.
The Voluntary Scheme for Branded Medicine Pricing, Access and Growth (VPAG) investment program made its official debut Wednesday, according to a release from the U.K.’s top biopharma trade organization, the Association of the British Pharmaceutical Industry (ABPI).
The program—which combines the powers of the country’s Department of Health and Social Care, England’s National Health Service (NHS) and ABPI—has already snared an up to 400 million pound sterling ($527 million) investment to help accelerate patient access to cutting-edge drugs, bolster clinical trials and improve medicine manufacturing in the U.K. over the next five years.
Additionally, 18 new...
Today's Sponsors
Today's Sponsor